Clinical Trial Update: Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial assessing safety and immunogenicity of the Klebsiella pneumoniae tetravalent bioconjugate vaccine Kleb4V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Klebsiella Pneumoniae Infection

Drugs mentioned

• Kleb4V (Klebsiella pneumoniae tetravalent bioconjugate vaccine)

Snippet

Sponsor: LimmaTech Biologics AG | Conditions: Klebsiella Pneumoniae Infection | Phase 1, Phase 2 | Status: COMPLETED